Maspin is up-regulated in premalignant prostate epithelia

Christopher R. Pierson, Richard McGowen, David Grignon, Wael Sakr, Jyotirmoy Dey, Shijie Sheng

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

BACKGROUND. Maspin, a novel serine protease inhibitor, has been shown to inhibit prostate tumor cell motility and invasion in vitro and to inhibit prostate tumor growth and metastasis in vivo. Maspin expression in high-grade prostate carcinoma (PC) is reduced compared with that in low-grade PC. Interestingly, however, compared with low-grade PC, benign secretory prostate epithelial cells express significantly less maspin. This observation appears paradoxical to a putative tumor suppressive role of maspin in prostate carcinogenesis, and this finding issue needs to be clarified. METHODS. We examined maspin expression simultaneously in benign basal cells, benign secretory cells, high-grade prostate intraepithelial neoplasia (HGPIN), low-grade PC, and high-grade PC in 46 radical prostatectomy specimens plus 51 autopsy prostate glands by a combination of immunohistochemistry and in situ hybridization. RESULTS. Benign basal cells consistently expressed maspin at a high level. In PC, the loss of basolateral maspin expression coincides with loss of the basal cell layer. Maspin expression in secretory cells, on the other hand, appears to undergo a biphasic differential regulation, i.e., essentially absent in benign secretory cells, dramatically up-regulated in HGPIN, then progressively down-regulated through low-grade PC to high-grade PC. Maspin expression in PC is inversely correlated with tumor grade. Furthermore, maspin expression in HGPIN is inversely correlated with the Gleason's grade of the adjacent PC. CONCLUSIONS. An up-regulation of maspin expression precedes, rather than occurs at, the critical transition from premalignant prostate lesion of HGPIN to PC. Our data suggest maspin may mark an important transitional phase and play an important role in the premalignancy of the prostate gland.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalProstate
Volume53
Issue number4
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Prostate
Epithelium
Carcinoma
Neoplasms
SERPIN-B5
Serine Proteinase Inhibitors
Prostatectomy

Keywords

  • Autopsy specimens
  • Benign prostate epithelium
  • Carcinoma
  • HGPIN
  • Radical prostatectomy
  • Tumor suppressor

ASJC Scopus subject areas

  • Urology

Cite this

Pierson, C. R., McGowen, R., Grignon, D., Sakr, W., Dey, J., & Sheng, S. (2002). Maspin is up-regulated in premalignant prostate epithelia. Prostate, 53(4), 255-262. https://doi.org/10.1002/pros.10107

Maspin is up-regulated in premalignant prostate epithelia. / Pierson, Christopher R.; McGowen, Richard; Grignon, David; Sakr, Wael; Dey, Jyotirmoy; Sheng, Shijie.

In: Prostate, Vol. 53, No. 4, 01.12.2002, p. 255-262.

Research output: Contribution to journalArticle

Pierson, CR, McGowen, R, Grignon, D, Sakr, W, Dey, J & Sheng, S 2002, 'Maspin is up-regulated in premalignant prostate epithelia', Prostate, vol. 53, no. 4, pp. 255-262. https://doi.org/10.1002/pros.10107
Pierson CR, McGowen R, Grignon D, Sakr W, Dey J, Sheng S. Maspin is up-regulated in premalignant prostate epithelia. Prostate. 2002 Dec 1;53(4):255-262. https://doi.org/10.1002/pros.10107
Pierson, Christopher R. ; McGowen, Richard ; Grignon, David ; Sakr, Wael ; Dey, Jyotirmoy ; Sheng, Shijie. / Maspin is up-regulated in premalignant prostate epithelia. In: Prostate. 2002 ; Vol. 53, No. 4. pp. 255-262.
@article{454aae33058f42adae8d8b16582bba0f,
title = "Maspin is up-regulated in premalignant prostate epithelia",
abstract = "BACKGROUND. Maspin, a novel serine protease inhibitor, has been shown to inhibit prostate tumor cell motility and invasion in vitro and to inhibit prostate tumor growth and metastasis in vivo. Maspin expression in high-grade prostate carcinoma (PC) is reduced compared with that in low-grade PC. Interestingly, however, compared with low-grade PC, benign secretory prostate epithelial cells express significantly less maspin. This observation appears paradoxical to a putative tumor suppressive role of maspin in prostate carcinogenesis, and this finding issue needs to be clarified. METHODS. We examined maspin expression simultaneously in benign basal cells, benign secretory cells, high-grade prostate intraepithelial neoplasia (HGPIN), low-grade PC, and high-grade PC in 46 radical prostatectomy specimens plus 51 autopsy prostate glands by a combination of immunohistochemistry and in situ hybridization. RESULTS. Benign basal cells consistently expressed maspin at a high level. In PC, the loss of basolateral maspin expression coincides with loss of the basal cell layer. Maspin expression in secretory cells, on the other hand, appears to undergo a biphasic differential regulation, i.e., essentially absent in benign secretory cells, dramatically up-regulated in HGPIN, then progressively down-regulated through low-grade PC to high-grade PC. Maspin expression in PC is inversely correlated with tumor grade. Furthermore, maspin expression in HGPIN is inversely correlated with the Gleason's grade of the adjacent PC. CONCLUSIONS. An up-regulation of maspin expression precedes, rather than occurs at, the critical transition from premalignant prostate lesion of HGPIN to PC. Our data suggest maspin may mark an important transitional phase and play an important role in the premalignancy of the prostate gland.",
keywords = "Autopsy specimens, Benign prostate epithelium, Carcinoma, HGPIN, Radical prostatectomy, Tumor suppressor",
author = "Pierson, {Christopher R.} and Richard McGowen and David Grignon and Wael Sakr and Jyotirmoy Dey and Shijie Sheng",
year = "2002",
month = "12",
day = "1",
doi = "10.1002/pros.10107",
language = "English (US)",
volume = "53",
pages = "255--262",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Maspin is up-regulated in premalignant prostate epithelia

AU - Pierson, Christopher R.

AU - McGowen, Richard

AU - Grignon, David

AU - Sakr, Wael

AU - Dey, Jyotirmoy

AU - Sheng, Shijie

PY - 2002/12/1

Y1 - 2002/12/1

N2 - BACKGROUND. Maspin, a novel serine protease inhibitor, has been shown to inhibit prostate tumor cell motility and invasion in vitro and to inhibit prostate tumor growth and metastasis in vivo. Maspin expression in high-grade prostate carcinoma (PC) is reduced compared with that in low-grade PC. Interestingly, however, compared with low-grade PC, benign secretory prostate epithelial cells express significantly less maspin. This observation appears paradoxical to a putative tumor suppressive role of maspin in prostate carcinogenesis, and this finding issue needs to be clarified. METHODS. We examined maspin expression simultaneously in benign basal cells, benign secretory cells, high-grade prostate intraepithelial neoplasia (HGPIN), low-grade PC, and high-grade PC in 46 radical prostatectomy specimens plus 51 autopsy prostate glands by a combination of immunohistochemistry and in situ hybridization. RESULTS. Benign basal cells consistently expressed maspin at a high level. In PC, the loss of basolateral maspin expression coincides with loss of the basal cell layer. Maspin expression in secretory cells, on the other hand, appears to undergo a biphasic differential regulation, i.e., essentially absent in benign secretory cells, dramatically up-regulated in HGPIN, then progressively down-regulated through low-grade PC to high-grade PC. Maspin expression in PC is inversely correlated with tumor grade. Furthermore, maspin expression in HGPIN is inversely correlated with the Gleason's grade of the adjacent PC. CONCLUSIONS. An up-regulation of maspin expression precedes, rather than occurs at, the critical transition from premalignant prostate lesion of HGPIN to PC. Our data suggest maspin may mark an important transitional phase and play an important role in the premalignancy of the prostate gland.

AB - BACKGROUND. Maspin, a novel serine protease inhibitor, has been shown to inhibit prostate tumor cell motility and invasion in vitro and to inhibit prostate tumor growth and metastasis in vivo. Maspin expression in high-grade prostate carcinoma (PC) is reduced compared with that in low-grade PC. Interestingly, however, compared with low-grade PC, benign secretory prostate epithelial cells express significantly less maspin. This observation appears paradoxical to a putative tumor suppressive role of maspin in prostate carcinogenesis, and this finding issue needs to be clarified. METHODS. We examined maspin expression simultaneously in benign basal cells, benign secretory cells, high-grade prostate intraepithelial neoplasia (HGPIN), low-grade PC, and high-grade PC in 46 radical prostatectomy specimens plus 51 autopsy prostate glands by a combination of immunohistochemistry and in situ hybridization. RESULTS. Benign basal cells consistently expressed maspin at a high level. In PC, the loss of basolateral maspin expression coincides with loss of the basal cell layer. Maspin expression in secretory cells, on the other hand, appears to undergo a biphasic differential regulation, i.e., essentially absent in benign secretory cells, dramatically up-regulated in HGPIN, then progressively down-regulated through low-grade PC to high-grade PC. Maspin expression in PC is inversely correlated with tumor grade. Furthermore, maspin expression in HGPIN is inversely correlated with the Gleason's grade of the adjacent PC. CONCLUSIONS. An up-regulation of maspin expression precedes, rather than occurs at, the critical transition from premalignant prostate lesion of HGPIN to PC. Our data suggest maspin may mark an important transitional phase and play an important role in the premalignancy of the prostate gland.

KW - Autopsy specimens

KW - Benign prostate epithelium

KW - Carcinoma

KW - HGPIN

KW - Radical prostatectomy

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=0036892902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036892902&partnerID=8YFLogxK

U2 - 10.1002/pros.10107

DO - 10.1002/pros.10107

M3 - Article

VL - 53

SP - 255

EP - 262

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -